Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?

Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?

Our indicative theme of Gene Editing stocks remains down by about 11% year-to-date, meaningfully underperforming the S&P 500 which is up by about 19% over the same period. In fact, if we exclude a single stock Intellia Therapeutics, which is up by about 2.4x year-to-date, the other stocks are down..